Thema: Studie: Peg-Interferon Alpha-2B alone or in Combi with Thalidomide
Studie: Peg-Interferon Alpha-2B alone or in Combi with Thalidomide
Katja[a]
10.10.2002 18:46:05
A Randomized Phase II Study of Peg-Interferon Alpha-2B (Peg-Intron) Alone or in Combination with Thalidomide in Adults with Recurrent High-Grade Gliomas
Phase: Phase 2
Age Group: Adults Only
Min Karnofsky Score: 60
Requires occasional assistance but is able to care for most of own needs
Conditions:
Prior Surgery is Allowed
Prior Radiation is Allowed
Prior Chemotherapy is Allowed
Patients with histiologically proven supratentorial malignant primary gliomas. Tumor progression by MRI/CT scan. Failed prior radiation therapy. Patients may have had treatment for no more than two prior relapses. Recovered from the tosic effects of chemotherapy. No prior therapy with Peg-Intron or thalidomide.
Tumor Types:
Anaplastic Astrocytoma
Glioblastoma Multiforme
Mixed Glioma
Oligodendroglioma High Grade
Comments:
Patients are randomized to receive either Peg-Intron alone or in combination with thalidomide. Patients on arm A will be treated with weekly subcutaneous Peg-Intron injections. Patients on arm B will also receive daily thalidomide. All patients will be treated for 6 weeks then have a repeat MRI/CT scan of the brain to assess disease response.
Treatment Type: Chemotherapy
Contact:
Howard Fine MD
Branch, Chief
National Cancer Institute and National Institute of neurologic Disorder and Stroke
Bloch Bldg 82, MSC 8200
9030 Old Georgetown Road
Bethesda, MD 20892-8200 USA
Phone: 301-402-6298
Fax: (301)480-2246
Phase: Phase 2
Age Group: Adults Only
Min Karnofsky Score: 60
Requires occasional assistance but is able to care for most of own needs
Conditions:
Prior Surgery is Allowed
Prior Radiation is Allowed
Prior Chemotherapy is Allowed
Patients with histiologically proven supratentorial malignant primary gliomas. Tumor progression by MRI/CT scan. Failed prior radiation therapy. Patients may have had treatment for no more than two prior relapses. Recovered from the tosic effects of chemotherapy. No prior therapy with Peg-Intron or thalidomide.
Tumor Types:
Anaplastic Astrocytoma
Glioblastoma Multiforme
Mixed Glioma
Oligodendroglioma High Grade
Comments:
Patients are randomized to receive either Peg-Intron alone or in combination with thalidomide. Patients on arm A will be treated with weekly subcutaneous Peg-Intron injections. Patients on arm B will also receive daily thalidomide. All patients will be treated for 6 weeks then have a repeat MRI/CT scan of the brain to assess disease response.
Treatment Type: Chemotherapy
Contact:
Howard Fine MD
Branch, Chief
National Cancer Institute and National Institute of neurologic Disorder and Stroke
Bloch Bldg 82, MSC 8200
9030 Old Georgetown Road
Bethesda, MD 20892-8200 USA
Phone: 301-402-6298
Fax: (301)480-2246
Katja[a]
